TSLX

TSLX is a well-run business development company: it originates floating-rate loans to private companies, and the 10-K confirms that "substantially all of our investments" lack readily available market quotations and are marked to fair value "in good faith" by the Board with input from independent third-party valuation firms. That Level-3 valuation regime is the structural caveat behind every number — book equity of $1.61B is an appraisal, not a market price — but the manager's process (quarterly, audit-committee and third-party reviewed) is disciplined and the leverage is conservative: liabilities/equity of just 1.13x sits well inside the regulatory cap, with long-term debt down 8.3% YoY. With stockholders' equity of $1.61B over 94.7M shares, NAV is ~$17.00, so at $17.08 the stock trades essentially at book — a fair, not cheap, price for a quality BDC.

The income case is the whole case. Dividends paid of $170M almost exactly match net income of $171M (~1.0x coverage), and against the $17.08 price that ~$1.80/share distribution is a ~10.5% yield — closely tracking the 10.6% ROE. For a RIC that must distribute its earnings, this is the engine. The problem is direction: net income has stepped down three straight years ($222M → $187M → $171M) and diluted EPS fell 10.8% to $1.81. For a floating-rate lender that is the rate-cut signature — as base rates ease, net investment income compresses — and the MD&A's focus on interest-rate and FX hedging (interest-rate swaps tied to the 2026–2030 Notes) underscores that NII, not the dividend policy, is the variable to watch.